Elanco Animal Health (ELAN) Other Accumulated Expenses (2017 - 2026)
Elanco Animal Health (ELAN) reported Other Accumulated Expenses of $817.0 million for Q1 2026, up 41.84% on a YoY basis from $576.0 million in Q1 2025, and up 10.55% sequentially from $739.0 million in Q4 2025.
Elanco Animal Health (ELAN) Other Accumulated Expenses (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Other Accumulated Expenses data on file, last reported at $817.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 41.84% year-over-year to $817.0 million; the trailing twelve-month figure through Mar 2026 stood at $817.0 million (up 41.84% YoY), and the FY2025 full-year result was $739.0 million, up 58.58% from the prior year.
- Other Accumulated Expenses grew to $817.0 million in Q1 2026, from $739.0 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $817.0 million in Q1 2026 to a low of $377.0 million in Q1 2023.
- A 5-year average of $551.4 million and a median of $559.0 million in 2023 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses slipped 23.56% in 2022 and soared 58.58% in 2025, its largest moves.
- Tracing ELAN's Other Accumulated Expenses over 5 years: stood at $454.0 million in 2022, then decreased by 9.91% to $409.0 million in 2023, then rose by 13.94% to $466.0 million in 2024, then soared by 58.58% to $739.0 million in 2025, then grew by 10.55% to $817.0 million in 2026.
- Business Quant data shows ELAN's Other Accumulated Expenses at $817.0 million in Q1 2026, $739.0 million in Q4 2025, and $665.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 817.00 Mn |
| Dec 31, 2025 | 739.00 Mn |
| Sep 30, 2025 | 665.00 Mn |
| Jun 30, 2025 | 596.00 Mn |
| Mar 31, 2025 | 576.00 Mn |
| Dec 31, 2024 | 466.00 Mn |
| Sep 30, 2024 | 685.00 Mn |
| Jun 30, 2024 | 510.00 Mn |
| Mar 31, 2024 | 574.00 Mn |
| Dec 31, 2023 | 409.00 Mn |
| Sep 30, 2023 | 574.00 Mn |
| Jun 30, 2023 | 559.00 Mn |
| Mar 31, 2023 | 377.00 Mn |
| Dec 31, 2022 | 454.00 Mn |
| Sep 30, 2022 | 435.00 Mn |
| Jun 30, 2022 | 499.00 Mn |
| Mar 31, 2022 | 438.00 Mn |
| Dec 31, 2021 | 433.00 Mn |
| Sep 30, 2021 | 390.00 Mn |
| Jun 30, 2021 | 502.00 Mn |